AlphAIAlphAI — Financial news for AI agents
intelligencer.caSEP 152 min read$OSTX

OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing

OS Therapies (OSTX) announced full alignment with UK MHRA and EU EMA for its Conditional Marketing Authorisation Application (CMAA) for OST-HER2. The company expects to submit the CMAA soon and begin a confirmatory Phase 3 trial in Q4 2026. OST-HER2 has received multiple designations from the FDA and EMA, including Orphan Drug and Fast Track.

Original reporting
intelligencer.ca
Published Sep 15, 2026, 12:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 12:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing — source image
Source · intelligencer.ca
Decision brief

The 30-second read

$OSTXBullishHigh
01

Why it matters

Regulatory alignment is a decisive step toward market entry, likely reducing discount to risk and attracting investor interest ahead of the CMAA filing.

02

Market read

The announcement removes a major regulatory hurdle, setting up a near‑term catalyst for OSTX and potentially influencing peer biotech valuations.

03

What to watch

Potential competition from other HER2‑targeted therapies and the need for FDA approval remain uncertainties.

Relevance 8/10Novelty 9/10Timing: mid‑September 2026 CMAA filing window

Background

OS Therapies (OSTX) is a clinical‑stage company developing Listeria‑based immunotherapies for osteosarcoma, with orphan and fast‑track designations in the US and EU.

Company-level read

Ticker impact

$OSTXBullishHigh confidence
Context

OS Therapies announced full alignment with the UK MHRA and EU EMA for its pending Conditional Marketing Authorisation Application, with a CMAA submission expected in the coming weeks.

Expected impact

Potential short‑term upside of 10‑15% if the CMAA is filed as scheduled.

Evidence & confidence

The alignment removes regulatory uncertainty and signals progress toward market approval, a material catalyst for a clinical‑stage biotech.

Market effects

Sector

Strengthens the oncology biotech sector by showing regulatory pathways for gene‑edited therapies.

Regional

Positive for UK and EU biotech investors tracking rare‑disease approvals.

Global

Highlights cross‑border regulatory cooperation, relevant to global biotech pipelines.

Counterpoint

What could challenge this read

If the Phase 3 trial faces delays, the regulatory alignment may not translate into price gains.

Key entities

  • Executive
    Paul Romness

    Chairman & CEO of OS Therapies, quoted on the regulatory alignment.

  • Regulator
    MHRA

    UK Medicines and Healthcare products Regulatory Agency, granted alignment on historical control data.

  • Regulator
    EMA

    European Medicines Agency, aligned on CMAA design and trial plan.

Read at source← All news

Related articles

OCT 6
$OSTXMedAI 8/10

OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial

OS Therapies (NYSE American: OSTX) reported a 72.7% 3-year overall survival rate for OST-HER2-treated patients in its Phase 2b trial, compared to 45.8% in historical controls. The company plans to submit regulatory applications for early market access in the U.S., U.K., Europe, and Australia. OST-HER2 has received multiple designations from the FDA and EMA, including Orphan Drug and Fast Track.

finance.yahoo.com2 min
OCT 1
$OSTXLow

OS Therapies: OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer

OS Therapies (NYSE American: OSTX) appointed Kerry Clem as CCO and Frank Knuettel II as CFO. Clem will lead commercialization of Herlystic, their lead immunotherapy for osteosarcoma, with U.S. launch planned post-FDA approval. Knuettel brings financial expertise. The company anticipates regulatory filings in Q4 2026 and has received tax credits for R&D.

finanznachrichten.de2 min
SEP 24
$OSTXMedAI 8/10

OS Therapies: OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)

OS Therapies (NYSE American: OSTX) announced that the World Health Organization approved 'Herlystic' as the brand name for OST-HER2, a gene-edited cancer immunotherapy. The company plans to initiate regulatory submissions for early market access in the U.K., U.S., Europe, and Australia. OST-HER2 has received multiple designations from the FDA and EMA, and the company aims to file for a Biologics License Application in the U.S. in 2026.

finanznachrichten.de2 min
SEP 21
$OSTXMedAI 8/10

OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis

OS Therapies (OSTX) updated its global regulatory coordination for OST-HER2 under Project Orbis. The U.K.'s MHRA will lead the process, with a Phase 3 trial set to begin in mid-2026. The FDA aligned on the study design, and the company aims to submit a CMAA soon. OST-HER2 has received multiple designations from the FDA, EMA, and MHRA.

intelligencer.ca2 min
SEP 17
$OSTXMedAI 8/10

OS Therapies: OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program

OS Therapies (OSTX) aligned with the FDA on its Phase 3 trial design for OST-HER2, a treatment for metastatic osteosarcoma. The company will join Project Orbis, a global regulatory initiative, and aims to submit a BLA in Q4 2026. OST-HER2 has received multiple designations from the FDA and EMA, and a successful BLA could make the company eligible for a Priority Review Voucher.

finanznachrichten.de2 min